You are viewing the site in preview mode
Skip to main content
|
PATIENTS VS CONTROLS
|
|---|
|
Cohort 1
|
N°
|
Cohort 2
|
N°
|
|
Patients
|
72
|
Controls
|
82
|
|
Patients < 12 y
|
42
|
Controls < 12 y
|
46
|
|
Patients ≥ 12y
|
30
|
Controls ≥ 12y
|
36
|
|
SUBGROUPS OF CONTROLS
|
|
Cohort 1
|
N°
|
Cohort 2
|
N°
|
|
< 12y
|
46
|
≥ 12y
|
36
|
|
Females
|
41
|
Males
|
41
|
|
SUBGROUPS OF PATIENTS
|
|
Cohort 1
|
N°
|
Cohort 2
|
N°
|
|
Patients < 12y
|
42
|
≥ 12y
|
30
|
|
Females
|
42
|
Males
|
30
|
|
Patients with MMD < 5
|
42
|
Patients with MMD ≥ 5
|
30
|
|
Patients with photophobia and phonophobia
|
41
|
Patients with photophobia or phonophobia
|
62
|
|
Patients with photophobia
|
50
|
Patients without photophobia
|
22
|
|
Patients with nausea and/or vomiting
|
38
|
Patients without nausea and/or vomiting
|
34
|
-
The table illustrates the statistical analysis performed separately on cortical thickness and gyrification between: healthy patients and patients; subgroups of healthy controls and subgroups of patients. Cohort 1 and cohort 2 indicate the two groups of patients compared for each statistical analysis and n° indicates the number of patients forming a particular cohort.
-
MMD: migraine monthly days.